ABBV · News · 20261031N
Revenue Performance and Mix
AbbVie Inc. · 2026-10-31 · Importance 58 · Surprise 40 · No source text
AbbVie reported Q3 2026 revenue of $17.404 billion, up 10.3% year over year. SKYRIZI sales were $5.78 billion and RINVOQ sales were $2.71 billion. Those products offset a decline in HUMIRA sales.
Key facts
- AbbVie reported Q3 2026 revenue of $17.404 billion, up 10.3% year over year. source
- AbbVie’s Skyrizi sales reached $5.78 billion. source
- AbbVie’s Rinvoq sales reached $2.71 billion. source
- AbbVie reported Q3 2026 sales of US$17.4b. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | +9.6% | AbbVie reported Q3 2026 revenue of $17.404 billion, up 10.3% year over year. |